Search
Returning search results with filters:
Remove filter for
Audience: Health professionals
Remove filter for
Category: Drugs
Remove filter for
Last updated: 2022
Clear all
Type
Audience
Category
Issue
Last updated
Recall class
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.
Displaying 1 - 15 of 20 items.
The affected lots may contain glass particles.
RecallHealth product recall | 2022-08-02
All lots contain an undeclared ingredient (sildenafil) that is listed on the prescription drug list.
RecallHealth product recall | 2022-06-01
EVUSHELD (tixagevimab and cilgavimab for injection) was authorized by Health Canada on April 14, 2022. In order to provide rapid access to EVUSHELD in the context of the global COVID-19 pandemic, AstraZeneca will distribute product vials and cartons with…
AlertHealth professional risk communication | 2022-04-14
UPDATED INFORMATION – May 6, 2022
Further to the communication below, issued on March 15, 2022, regarding the potential for the presence of particulate matter in vials of Sodium Acetate Injection, USP (DIN 02139529) from lot 6126554, Fresenius Kabi…
AlertHealth professional risk communication | 2022-03-15
UPDATED INFORMATION - March 11, 2022
On March 10, 2022, for the second time, the Federal Court set aside Health Canada’s decision to authorize RUZURGI (amifampridine), and the second Notice of Compliance (NOC) that had been issued on June 24, 2021…
AlertHealth professional risk communication | 2022-03-11
Intravenous bags of Baxter’s 0.9% Sodium Chloride Injection, USP 500 mL and Lactated Ringer’s Injection, USP 500 mL from certain lots have the potential to leak when administered under pressure infusion due to a weak seal formation.
Affected lots are…
AlertHealth professional risk communication | 2022-03-09
Intravenous bag may be leaking in affected lot
RecallHealth product recall | 2022-03-07
Solution bags may be leaking in affected lot.
RecallHealth product recall | 2022-02-28
NUVAXOVID was authorized by Health Canada on February 17, 2022. In order to provide earlier access to NUVAXOVID in the context of the global pandemic, Novavax, Inc. will distribute product vials, cartons and package inserts that are in English only for a…
AlertHealth professional risk communication | 2022-02-23
Elevated reporting rate of hypersensitivity reactions in affected lot.
RecallHealth product recall | 2022-02-23
The assay is out of specification in the affected lot
RecallHealth product recall | 2022-02-23
Impurities could be out of specification in affected lots.
RecallHealth product recall | 2022-02-04
An increased incidence of intraocular inflammation (IOI), including retinal vasculitis (RV) and retinal vascular occlusion (RO), was observed in patients who received BEOVU 6 mg with every 4 weeks (q4 week) dosing beyond the first 3 doses compared to…
AlertHealth professional risk communication | 2022-02-03
The dissolution is out of specification in the affected lot(s).
RecallHealth product recall | 2022-01-31
Affected lots exceeds concentration limit for N-nitrosodimethylamine (NDMA) at the 36-month stability testing timepoint.
RecallHealth product recall | 2022-01-26